Hansoh Pharmaceutical Group Company Limited specializes in the research, development, production, and commercialization of pharmaceutical products and it primarily focuses on innovative drugs. The company is recognized for its commitment to enhancing…
Analysis
Middle-of-the-road
Hansoh Pharmaceutical Group Company Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is expensive. The owner-earnings multiple stands at 28.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 11% a year, against analyst forecasts of 7%. The gap between price and consensus is worth watching: demanding expectations.
Growth is moderate; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 202677
75
2026
All-time high
77
Feb 2026
All-time low
75
Jun 2026
Average rank
76
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
25
—
—
—
Price/Book
12
—
—
—
Dividend Yield
69
—
—
—
Value (overall)
17
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.